Bacillus velezensis HBXN2020 alleviates Salmonella Typhimurium-induced colitis by improving intestinal barrier integrity and reducing inflammation

Linkang Wang; Haiyan Wang; Xinxin Li; Mengyuan Zhu; Dongyang Gao; Dayue Hu; Zhixuan Xiong; Xiangmin Li; Ping Qian

doi:10.7554/eLife.93423.2

eLife assessment

In this useful study, Wang and colleagues investigate the potential probiotic effects of Bacillus velezensis in a murine model. They provide solid evidence that B. velezensis limits the growth of Salmonella typhimurium in lab culture and in mice, together with beneficial effects on the microbiota. The overall presentation of the manuscript and logical flow requires improvement and the work will be of interest to infectious disease researchers.

https://doi.org/10.7554/eLife.93423.2.sa3

Significance of findings

useful: Findings that have focused importance and scope

landmark
fundamental
important
valuable
useful

Strength of evidence

solid: Methods, data and analyses broadly support the claims with only minor weaknesses

exceptional
compelling
convincing
solid
incomplete
inadequate

During the peer-review process the editor and reviewers write an eLife assessment that summarises the significance of the findings reported in the article (on a scale ranging from landmark to useful) and the strength of the evidence (on a scale ranging from exceptional to inadequate). Learn more about eLife assessments

Abstract

Bacillus velezensis is a species of Bacillus that has been widely investigated because of its broad-spectrum antimicrobial activity. However, most studies on Bacillus velezensis have focused on the biocontrol of plant diseases, with few reports on antagonizing Salmonella Typhimurium infections. In this investigation, it was discovered that Bacillus velezensis HBXN2020, which was isolated from healthy black pigs, possessed strong anti-stress and broad-spectrum antibacterial activity. Importantly, Bacillus velezensis HBXN2020 did not cause any adverse side effects in mice when administered at various doses (1 × 10⁷, 1 × 10⁸, and 1 × 10⁹ CFU) for 14 d. Supplementing Bacillus velezensis HBXN2020 spores, either as a curative or preventive measure, dramatically reduced the levels of Salmonella Typhimurium ATCC14028 in the mice’s feces, ileum, cecum, and colon, as well as the disease activity index (DAI), in a model of colitis caused by this pathogen in mice. Additionally, supplementing Bacillus velezensis HBXN2020 spores significantly regulated cytokine levels (TNF-α, IL-1β, IL-6, and IL-10) and maintained the expression of tight junction proteins and mucin protein. Most importantly, adding Bacillus velezensis HBXN2020 spores to the colonic microbiota improved its homeostasis and increased the amount of beneficial bacteria (Lactobacillus and Akkermansia). All together, Bacillus velezensis HBXN2020 can improve intestinal microbiota homeostasis and gut barrier integrity and reduce inflammation to help treat bacterial colitis.

Introduction

Salmonella Typhimurium (S. Typhimurium) is a major foodborne zoonotic pathogen that can cause diarrhea and colitis in humans and animals (Fabrega and Vila, 2013; Yang et al., 2021). According to reports, Salmonella infections are common in both industrialized and developing nations, posing a serious risk to public health and resulting in significant financial losses (Katiyo et al., 2019; Mohan et al., 2019). At present, antibiotics remain one of the most effective treatment strategies for Salmonella infections. However, numerous studies have reported that the prolonged use or misuse of antibiotics can lead to environmental pollution, an increase in multi-drug-resistant (MDR) bacteria, as well as gastrointestinal microbiota dysbiosis (Ferri et al., 2017; Paulson et al., 2015; Reyman et al., 2022). In order to tackle Salmonella infections, a hunt for novel antimicrobial drugs is now underway.

More research has recently demonstrated the critical role gut microbiota plays in reducing intestinal inflammation (Cristofori et al., 2021) and mending the intestinal barrier (Ohland and Macnaughton, 2010; Wang et al., 2020). The use of probiotics is a popular approach to modulating intestinal microbiota nowadays. Among all probiotics, Bacillus is one of the most popular probiotic species because of its ability to form endospores that survive gastric transit, storage and delivery conditions (Gu et al., 2015). Furthermore, Bacillus species can generate extracellular enzymes and antimicrobial metabolites that inhibit enteric pathogens, which lowers the risk of infection and enhances nutrient utilization (Abdhul et al., 2015; Ouattara et al., 2017).

The recently identified Bacillus velezensis (B. velezensis) species of the Bacillus genus has a large capacity to generate a variety of secondary metabolites that possess broad-spectrum antibacterial activity (Ye et al., 2018). Previous studies have reported that B. velezensis exhibits varying degrees of probiotic effects on plants, livestock, poultry and fish. For instance, the combined use of B. velezensis SQR9 mutant and FZB42 improved root colonization and the production of secondary metabolites that are beneficial to cucumber (Shao et al., 2022). B. velezensis isolated from yaks was shown to enhance growth performance and ameliorate blood parameters related to inflammation and immunity in mice (Li et al., 2019). The dietary B. velezensis supplementation can regulate the innate immune response in the intestine of crucian carp and reduce the degree of intestinal inflammation damage induced by A. veronii (Zhang et al., 2019). Few studies have been conducted on the treatment or prevention of colitis caused by S. Typhimurium; instead, the majority of investigations on B. velezensis focused on the biocontrol of fungal infections in plants.

A strain of B. velezensis HBXN2020 with broad-spectrum antibacterial activity was selected from a vast number of Bacillus strains for this study. We aimed to investigate the effectiveness of B. velezensis HBXN2020 in alleviating S. Typhimurium-induced mouse colitis and assessed the biological safety of B. velezensis HBXN2020. Notably, B. velezensis HBXN2020 can alleviate symptoms and colon tissue damage in experimental colitis, as indicated by markers such as S. Typhimurium loads, TNF-α and ZO-1 levels. Moreover, B. velezensis HBXN2020 also increases the abundance of beneficial bacteria, specifically Lactobacillus and Akkermansia, within the colon microbiota. As a result, this research supports the creation of probiotic-based microbial products as a substitute method of preventing Salmonella infections.

Results

Genomic Characteristics

HBXN2020’s complete genome was sequenced using the Illumina Hiseq and PacBio platforms. The results showed that HBXN2020 has a circular chromosome of 3,929,792 bp (Fig. 1A) with a GC content of 46.5%, including 3,744 protein-coding genes (CDS), 86 tRNA genes, and 27 rRNA genes (Table S1). Furthermore, the HBXN2020 genome also contains 13 different clusters of secondary metabolic synthesis genes. such as Fengycin (genomic position:1,865,856) and Difficidin (genomic position:2,270,091) (Table S2).

A phylogenetic tree based on genome-wide data from all 14 Bacillus strains demonstrated that the HBXN2020 belongs to the B. velezensis species (Fig. 1B). To further understand the classification status of HBXN2020, the online tool JSpeciesWS was used to calculate the average nucleotide identity (ANI) based on the BLAST (ANIb) method. As shown in Fig. S1, HBXN2020 was found to be a member of the B. velezensis species due to the high percentage of ANIb (more than 97%).

Growth curve and in vitro resistance against environmental assaults

The growth of B. velezensis HBXN2020 was assessed in flat-bottomed 100-well microtiter plates by measuring the values of OD₆₀₀ every hour using an automatic growth curve analyzer. After measurement, we found that B. velezensis HBXN2020 entered the logarithmic growth phase after 2 h, and reached a plateau after 10 h of culture (Fig. 2A).

Growth curve of *B. velezensis* HBXN2020 and its *in vitro* resistance against environmental assaults.
(A) Growth curves of *B. velezensis* HBXN2020 cultured in LB medium at 37°C, detection of OD₆₀₀ values at 1 h intervals in microplate reader. (B) Survival rate of endospore and vegetative cells of *B. velezensis* HBXN2020 after 30 min at different temperatures (37°C, 45°C, 55°C, 65°C, 75°C, 85°C or 95°C). Equal amounts of endospore and vegetative cells of HBXN2020 were exposed to the following: (C) acid solution (pH 2 to 7), (D) 0.3% bile salts, (E) SGF (pH 1.2) supplemented with pepsin, and (F) SIF (pH 6.8) containing trypsin at 37°C. At predetermined time points, 100 μL was taken from each sample, and tenfold serially diluted with sterile PBS (pH 7.2), and then spread on LB agar plates and cultured at 37°C for 12 h before bacterial counting. Each group was repeated three times (n = 3).

Next, we evaluated the effect of physical, chemical, and biological sterilization conditions such as high temperature, strong acidity, and enzyme preparation on the survival of B. velezensis HBXN2020. The survival rate of B. velezensis HBXN2020 showed a decreasing trend with increasing temperature (Fig. 2B), but this decrease was not obvious. In a strong acid environment (pH 2.0), B. velezensis HBXN2020 maintained a high survival rate (Fig. 2C), suggesting that B. velezensis HBXN2020 spores can survive under extreme conditions. Based on these results, we hypothesized that B. velezensis HBXN2020 spores might also exhibit improved survival in gastrointestinal tract environments. Therefore, we further evaluated the survival rate of B. velezensis HBXN2020 in bile salt (0.3%, v/v), simulated gastric fluid (pepsin 1 mg mL^-1, pH 1.2), and simulated intestinal fluid (trypsin 1 mg mL^-1, pH 6.8). As shown in Fig. 2D-F, B. velezensis HBXN2020 spores demonstrated significantly improved tolerance to these simulated gastrointestinal tract environments.

Antibiotic susceptibility of B. velezensis HBXN2020 and bacteriostasis effect in vitro

In order to assess B. velezensis HBXN2020’s drug resistance, 19 antibiotics that are frequently used in clinical settings were chosen. The results indicated that only polymyxin B had a relatively small inhibition zone diameter (less than 15 mm). Ampicillin, meropenem, minocycline, ofloxacin, and trimethoprim had the strongest inhibition on B. velezensis HBXN2020, with an inhibition zone diameter exceeding 30 mm (Fig. 3A). In addition, the experimental results showed that B. velezensis HBXN2020 was extremely sensitive to β-lactams, tetracyclines, and quinolone drugs. Then, we performed an inhibition test of B. velezensis HBXN2020 against seven common clinical pathogenic bacteria. The results showed that B. velezensis HBXN2020 had a similar inhibitory effect on standard and wild strains of Escherichia coli (E. coli), Salmonella, Staphylococcus aureus (S. aureus), and Clostridium perfringens (C. perfringens), as well as wild strains of Streptococcus suis (S. suis), Pasteurella multocida (P. multocida), and Actinobacillus pleuropneumoniae (A. pleuropneumoniae). Except for the wild strains of S. suisand A. pleuropneumoniae, the diameter of the inhibition zone of other strains was above 15 mm (Fig. 3B, S2), while the size of the inhibition zone of S. suis and A. pleuropneumoniae was also more than 12 mm.

Antibiotic susceptibility of *B. velezensis*HBXN2020 and bacteriostasis assay *in vitro*.
(A) The diameter of the antibacterial zone indicates the extent of sensitivity to antibiotics. (B) The diameter of the antibacterial zone indicates the extent of inhibition against pathogenic bacteria. The diameter of the antibacterial zone was measured with vernier caliper. Each group was repeated three times (n = 3). R, resistant; I, moderately sensitive; S, sensitive.

Biosafety evaluation of B. velezensis HBXN2020

We assessed the biological safety of B. velezensis HBXN2020 in a mouse model in order to ascertain its safety. After gavage with B. velezensis HBXN2020 spores for two weeks, we observed no significant difference in the body weight of each group of mice (Fig. 4A). The gene expression levels of TNF-α, IL-1β, IL-6, and IL-10 of colon from all groups of mice exhibited no remarkable changes (Fig. 4B). However, in the colon, mRNA levels of the barrier proteins ZO-1 and occludin were trending towards an increase compared with the control group (Fig. 4C). Additionally, blood routine tests and serum biochemistry tests were performed for mice in the control group and H-HBXN2020 group on the 14^th d after oral administration of B. velezensis HBXN2020 spores multiple times. As shown in Fig. 4D and S3, the blood parameters of mice after B. velezensis HBXN2020 treatment, including red blood cells (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), hemoglobin (HGB), white blood cells (WBC), platelets (PLT), hematocrit (HCT), and mean corpuscular hemoglobin concentration (MCHC), were consistent with those of healthy mice. The serum biochemical parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TBIL), serum creatinine (CREA), and blood urea nitrogen (BUN), were also within normal limits (Fig. 4E). The corresponding histological analysis of colon tissue from mice receiving low, medium, and high doses of B. velezensis HBXN2020 spores (L-HBXN2020, M-HBXN2020, and H-HBXN2020 groups, respectively) is presented in Fig. 4F. The colon tissue sections of mice in the test groups showed no significant differences compared to the control group. Additionally, there were no observable differences in the major organ tissues (heart, liver, spleen, lung, and kidney) of mice treated with the high dose of B. velezensis HBXN2020 spores compared to healthy mice (Fig. S4). The results of this trial show that B. velezensis HBXN2020 is safe to use and has no negative side effects in mice.

*In vivo* safety evaluation of *B. velezensis* HBXN2020 in a mouse model.
(A) Body weights changes of mice during gavage with *B. velezensis* HBXN2020 spores. Mice were treated with sterile PBS (Control group) or low-dose (L-HBXN2020 group), medium dose (M-HBXN2020 group), and high-dose (H-HBXN2020 group) of *B. velezensis* HBXN2020 spores. Weighing and gavage were performed once every two days during the experimental period (15 days). Data were shown as mean values ± SEM (n = 5). (B) The relative gene expression levels of inflammatory cytokines in the colon of mice measured by RT-qPCR. Data were shown as mean values ± SEM (n = 5). (C) The relative gene expression levels of barrier protein ZO-1, occludin, claudin and Muc2 in the colon of mice measured by RT-qPCR. Data were shown as mean values ± SEM (n = 5). (D) Major blood routine parameters and (E) serum biochemical parameters of mice in the control group and H-HBXN2020 group. Data were shown as mean values ± SEM (n = 3). (F) H&E stained colon sections in the different groups. Scale bar: 200 μm.

Oral administration of B. velezensis HBXN2020 spores alleviated S. Typhimurium-induced colitis

Testing both solid and liquid co-culture methods to see if B. velezensis HBXN2020 might suppress S. Typhimurium ATCC14028 (STm), the findings indicated that B. velezensis HBXN2020 decreased the development of STm in a dose-dependent manner (Fig. 5A, S5). Next, the therapeutic potential of B. velezensis HBXN2020 was evaluated in an STm-induced mouse colitis model. At days 1, 3, and 5 after STm infection, mice in the STm + HBXN2020 group were orally administered B. velezensis HBXN2020 spores by gavage (Fig. 5B), while the control group and STm + PBS group were treated with sterile PBS. Also, the number of excreted STm in feces was counted daily at the designated time points. As shown in Fig. 5C, there was a significant and continuous reduction in the number of STm in feces following treatment with B. velezensis HBXN2020 spores, while the number of B. velezensis HBXN2020 viable bacteria in feces is also gradually decreasing (Fig. S6A). The number of STm in mouse feces was reduced by 10 to 50 times compared to the STm + PBS group from day 2 to 7 post-treatment. B. velezensis HBXN2020 spore treatment also resulted in a 5 to 10-fold reduction in the number of STm in the ileum, cecum, and colon, respectively (Fig. 5D-F). The increased inhibition of STm after B. velezensis HBXN2020 spore treatment also resulted in less weight loss and a marked reduction (P < 0.001) in DAI scores in STm + HBXN2020 group mice (Fig. 5G-H). In addition, we also measured the colon length of the mice and found that the STm + PBS group had a significantly shorter colon length (P < 0.001) than the control group. However, compared to the STm + PBS group, the STm + HBXN2020 group exhibited a longer colon (P < 0.05) (Fig. 5I-J).

Oral *B. velezensis* HBXN2020 spores alleviated S. Typhimurium-induced experimental mouse colitis.
(A) *In vitro* Bacterial competition between STm and *B. velezensis* HBXN2020. STm were co-incubated with *B. velezensis* HBXN2020 at various ratios at 37°C with shaking. The growth of STm was reflected by bacterial counting per hour. (B) Experimental design for treatment in this study. Orally administrated with either PBS, or *B. velezensis* HBXN2020 spores by gavage at days 1, 3, and 5 after STm infection (5× 10⁷ CFU/mouse), respectively. All mice were euthanized at day 7 after STm infection. (C) Bacterial count of STm in mouse feces. Fecal samples were collected per day after STm infection and resuspended in sterile PBS (0.1 g of fecal resuspended in 1 mL of sterile PBS). One hundred microliters of each sample performed a serial of 10-fold dilutions and spread on selective agar plates (50 µg mL^-1 kanamycin) and incubated at 37°C for 12 h before bacterial counting. The bacterial loads of STm in (D) ileum, (E) cecum, and (F) colon. The cecum and colon were harvested and then homogenized. Statistical signifcance was evaluated using Student’s t-test (*, P < 0.05, **, P < 0.01, and ***, P < 0.001). (G) Daily body weight changes and (H) daily disease activity index (DAI) scores of mice with different treatment groups. Data were shown as mean values ± SEM (n = 8). Statistical signifcance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test. *, P < 0.05, **, P < 0.01, and ***, P < 0.001 relative to Control group; ^#, P < 0.05, ^##, P < 0.01, ^###, P < 0.001 relative to STm + HBXN2020 group. (I) Colonic tissue images. (J) The length of the colon from per group (n = 8). Statistical signifcance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, P < 0.05, **, P < 0.01, and ***, P < 0.001).

To further assess the impact of B. velezensis HBXN2020 on the intestinal tract, we histologically analyzed their colonic tissues. The results showed that mice treated with B. velezensis HBXN2020 spores exhibited a lower histology score (total scoring) (P < 0.05) (Fig. 6A, S6B) than mice not treated with the spores and were similar to that of healthy mice (control group). The colon tissue of mice not treated with B. velezensis HBXN2020 spores displayed higher histological scores, with significant crypt deformation, severe mucosal damage, and obvious inflammatory cell infiltration. These findings suggested that B. velezensis HBXN2020 can alleviate colon tissue damage. Moreover, we measured the mRNA levels of inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1 β), interleukin-6 (IL-6), and interleukin-10 (IL-10) in colon tissue using RT-qPCR analysis. As shown in Fig. 6B-D, the mRNA levels of TNF-α (P < 0.01), IL-1β (P < 0.05), and IL-6 (P < 0.05) in the colon tissue of STm-infected mice were significantly upregulated, indicating the successful establishment of the STm-induced colitis model. As expected, treatment with B. velezensis HBXN2020 spores led to a significant reduction in the mRNA levels of these pro-inflammatory cytokines, while the mRNA levels of the anti-inflammatory cytokine IL-10 were significantly increased (P < 0.01) (Fig. 6E), suggesting that B. velezensis HBXN2020 spores can alleviate the inflammatory reaction of the colon. Moreover, the mRNA expression levels of colonic epithelial barrier proteins, including ZO-1, ocludin, claudin, and Muc2, were also measured by RT-qPCR. Compared with the PBS-treated group, the B. velezensis HBXN2020 spores treatment group exhibited significantly upregulated mRNA expression levels of ZO-1 (P < 0.05), occludin (P < 0.05), claudin (P < 0.05), and Muc2 (P < 0.01) in the colon tissue (Fig. 6F-I), further demonstrating the ability of B. velezensis HBXN2020 to reduce damage to the colon epithelial barrier.

Oral *B. velezensis* HBXN2020 spores attenuated colonic damage and inflammatory reaction.
(A) H&E stained colon tissue sections. Scale bar: 200 μm. The relative gene expression levels of TNF-α (B), IL-1β (C), IL-6 (D), and IL-10 (E) were detected by RT-qPCR. Data were shown as mean values ± SEM (n = 6). The relative gene expression levels of ZO-1 (F), ocludin (G), claudin (H), and Muc2 (I) in colon tissue were detected by RT-qPCR. Data were shown as mean values ± SEM (n = 6). Statistical signifcance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, P < 0.05, **, P < 0.01, and ***, P < 0.001).

Next, we used 16S rRNA gene sequencing to investigate the impact of HBXN2020 spores on the makeup of the intestinal microbiota in mice treated with STm. The alpha diversity of colonic microbiota was evaluated using Sobs, Chao1, Shannon, and Simpson indices (OTU levels). Compared with the control and HBXN2020 group, the Sobs, Chao1, and Shannon indices of the STm + PBS group clearly decreased (Fig. 7A-C), while the Simpson index significantly increased (P < 0.05, Fig. 7D). Principle component analysis (PCA) based on Bray-Curtis distance showed that compared with the STm + PBS group, the gut microbiota composition of the STm + HBXN2020 group and the control group were more closer together (R= 0.3988, P = 0.001, Fig. 7E). We analyzed the community composition of colonic microbiota at the phylum and genus level, and the results revealed that the composition of the gut microbiota changed markedly after STm-induced mice. At the phylum level, the STm + PBS group increased the abundance of Verrucomicrobiota and Proteobacteria and decreased the abundance of Firmicutes, Patescibacteria, Desulfobacterota, and Actinobacteriota compared to the Control group (Fig. 7F). The HBXN2020 group increased the abundance of Bacteroidota and Firmicutes and decreased the abundance of Verrucomicrobiota compared with the Control group. On the contrary, the relative abundance of Firmicutes, Patescibacteria, Desulfobacterota, and Actinobacteriota in the STm + HBXN2020 group was significantly higher than that in the STm + PBS group. At the genus level, infection with S. Typhimurium ATCC14028 in the STm + PBS group dramatically reduced the relative abundance of norank_f_Muribaculaceae, Desulfovibrio and Lactobacillus (Fig. 7G, H-I) and enhanced the abundance of Bacteroides, Escherichia-Shigella, Salmonella, Alistipes, and Enterococcus compared to the Control group (Fig. 7G, J-K). The HBXN2020 group increased the abundance of norank_f_Muribaculaceae and Alloprevotella compared to the Control group. In contrast, the STm + HBXN2020 group significantly improved the relative abundance of norank_f_Muribaculaceae and Lactobacillus compared with the STm + PBS group (P < 0.01, P < 0.001, Fig. 7H-I). In addition, LEfSe analysis was also performed to identify specialized microbial communities between the STm + HBXN2020 group and the STm + PBS group and found that there was a clear difference in gut microbiota composition between them. The microbiota that played a major role in the STm + PBS group were harmful Enterobacterales (Fig. 7L), while the STm + HBXN2020 group was Candidatus_Saccharimonas.

Oral *B. velezensis* HBXN2020 spores regulated the composition of intestinal microbiota.
The α-diversity of the gut microbiota, determined by the (A) Sobs, (B) Chao1, (C) Shannon, and (D) Simpson diversity index. Data were shown as mean values ± SEM (n = 5). (E) The PCA plot showed the β-diversity of the gut microbiota based on Bray-Curtis distance at the OTU level. Heatmap of the community composition of colonic microbiota at the phylum (top 10 phyla) (F) and genus (top 30 genera) (G) level. Relative abundance of selected taxa (H) *norank_f_Muribaculaceae*, (I) *Lactobacillus*, (J) *Bacteroides*, and (K) *Escherichia-Shigella*. (L) Analysis of differences in the microbial communities by LEfSe (linear discriminant analysis (LDA score > 3.5) among different groups. Signifcance was evaluated by the Kruskal-Wallis test or ANOVA with Tukey’s multiple comparisons test (*, P < 0.05, **, P < 0.01, and ***, P < 0.001).

Prophylactic B. velezensis HBXN2020 spores alleviated S. Typhimurium-induced colitis

Based on the improved therapeutic efficacy of B. velezensis HBXN2020 in the treatment of STm-induced colitis in mice, we further explored its potential for disease prevention by evaluating pretreatment. Mice in the PBS + STm group and HBXN2020 + STm group were given the same amount of sterile PBS and B. velezensis HBXN2020 spores by gavage one week in advance. As shown in Fig. 8, compared with the PBS + STm group, oral administration of B. velezensis HBXN2020 spores as a preventive measure remarkably alleviated STm-induced colitis, including weight loss of mice (P < 0.01) (Fig. 8B), a significant reduction in DAI (P < 0.001) (the comprehensive score of weight loss, stool consistency, and blood in the feces, Fig. 8C), and the prevention of colon length shortening (Fig. 8D-E). However, the number of B. velezensis HBXN2020 viable bacteria in feces is also gradually decreasing with time prolonging (Fig. S8A). Furthermore, compared with the PBS + STm group, oral administration of B. velezensis HBXN2020 spores not only reduced the number of STm in mouse feces (Fig. 8F) but also decreased STm colonization in the ileum, cecum, and colon (Fig. 8G-H, S8B).

Prophylactic *B. velezensis* HBXN2020 spores attenuated the symptoms of S. Typhimurium-induced mouse colitis.
(A) Experimental design for treatment in this study. At days 1, 3, 5, and 7, each mouse in the HBXN2020 + STm group and PBS + STm group were received 200 μL (1×10⁸ CFU/mouse) of *B. velezensis* HBXN2020 spores or sterile PBS by gavage. Then, mice in PBS + STm group and HBXN2020 + STm group were orally inoculated with 200 μL (5×10⁷ CFU/mouse) of STm on day 7. On day 12, all mice were euthanized. (B) Daily body weight changes and (C) daily disease activity index (DAI) scores of mice with different groups following STm treatment. Data were shown as mean values ± SEM (n = 8). Statistical signifcance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test. *, P < 0.05, **, P < 0.01, and ***, P < 0.001 relative to Control group; ^#, P < 0.05, ^##, P < 0.01, ^###, P < 0.001 relative to HBXN2020 + STm group. (D) Colonic tissue images. (E) The length of the colon from per group (n = 8). (F) Bacterial count of STm in mouse feces. Fecal samples were collected every day after STm infection and resuspended in sterile PBS (0.1 g of fecal resuspended in 1 mL of sterile PBS). One hundred microliters of each sample performed a serial of 10-fold dilutions and spread on selective agar plates (50 µg mL^-1 kanamycin) and incubated at 37°C for 12 h before bacterial counting. The bacterial loads of STm in (G) cecum and (H) colon. The cecum and colon were harvested and then homogenized. Statistical signifcance was evaluated using Student’s t-test (*, P < 0.05, **, P < 0.01, and ***, P < 0.001).

Histological analysis further revealed that oral administration of B. velezensis HBXN2020 significantly reduced the infiltration of inflammatory cells, mucosal damage and the overall histological score of colon tissue (Fig. 9A, S8C). Additionally, the mRNA expression levels of proinflammatory cytokines, including TNF-α (P < 0.05), IL-1β (P < 0.05) and IL-6 (P < 0.01), in the colon tissue of mice pretreated with B. velezensis HBXN2020 spores were significantly decreased (Fig. 9B-D), while the mRNA levels of anti-inflammatory cytokine (IL-10) were significantly higher (P < 0.05) (Fig. 9E) than mice pretreated with PBS. In addition, compared to the group pretreated with PBS, the group pretreated with B. velezensis HBXN2020 spores showed a significant increase in mRNA expression levels of ZO-1 (P < 0.001), occludin (P < 0.05) and claudin (P < 0.05) in the colon tissue of mice (Fig. 9F-H). While there was no significant difference in Muc2 expression (p=0.252) (Fig. 9I), the results were consistent with those of the therapeutic experiments. Overall, these findings suggest that B. velezensis HBXN2020 can effectively alleviate the symptoms of STm-induced colitis and the associated damage to colon tissue.

Prophylactic *B. velezensis* HBXN2020 spores attenuated colonic damage and inflammatory reaction.
(A) H&E stained colon tissue sections. Scale bar: 200 μm. The relative gene expression levels of TNF-α (B), IL-1β (C), IL-6 (D), and IL-10 (E) were detected by RT-qPCR. Data were shown as mean values ± SEM (n = 6). The relative gene expression levels of ZO-1 (F), ocludin (G), claudin (H), and Muc2 (I) in colon tissue were detected by RT-qPCR. Data were shown as mean values ± SEM (n = 6). Statistical signifcance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, P < 0.05, **, P < 0.01, and ***, P < 0.001).

Next, we examined the impact of prophylactic B. velezensis HBXN2020 on the intestinal microbiota composition of STm-treated mice. Sobs, Chao1 index and Shannon index have changed to some extent between groups, but differences were not significant (Fig. 10A-C). Compared with the Control group, the Simpson index significantly decreased in the PBS + STm group (P < 0.05, Fig. 10D). However, compared to the PBS + STm group, Simpson index in the HBXN2020 + STm group did not change (Fig. 10D). PCA analysis showed significant separation between control and PBS + STm groups, while the HBXN2020 + STm group, HBXN2020 group, and the control group were clustered together (Fig. 10E). Next, we analyzed microbial community composition at the phylum and genus levels. At the phylum level, the PBS + STm group increased the abundance of Bacteroidota, Proteobacteria, Actinobacteriota, and Deferribacterota and reduced the abundance of Verrucomicrobiota, Firmicutes, Patescibacteria, and Desulfobacterota compared with the Control group (Fig. 10F). The HBXN2020 group increased the abundance of Bacteroidota compared to the control group. In contrast, compared to the PBS + STm group, the abundance of Firmicutes in the HBXN2020+STm group was significantly increased (P < 0.05). At the genus level, a depletion of Lactobacillus and Akkermansia (Fig. 10G, H-I) and an enrichment of Alistipes, Bacteroides, Escherichia-Shigella, Alloprevotella, Helicobacter, Enterococcus, and Salmonella were observed in PBS + STm group compared with the control (Fig. 10G, J-M). The enrichment with norank_f_Muribaculaceae and Alloprevotella was observed in the HBXN2020 group compared to the control. In contrast, an enrichment of Lactobacillus, Akkermansia, and Lachnospiraceae_NK4A136_group and a sharp decrease of Alistipes, Bacteroides, Escherichia-Shigella, Salmonella, and Enterococcus were observed in HBXN2020 + STm group compared to the PBS + STm group. LEfSe analysis showed that the abundance of Lactobacillus in the intestinal microbiota of mice was significantly increased after B. velezensis HBXN2020 treatment, while the abundance of harmful Enterobacterales in the untreated group was clearly increased (Fig. 10N).

Prophylactic *B. velezensis* HBXN2020 spores regulated the composition of gut microbiota.
(A to D) Alpha diversity of the intestinal microbiota. Data were shown as mean values ± SEM (n = 5). (E) The PCA plot showed the β-diversity among different microbial community groups based on Bray-Curtis distance at the OTU level. Heatmap of the community composition of colonic microbiota at the phylum (top 10 phyla) (F) and genus (top 30 genera) (G) level. Relative abundance of selected taxa (H) *Lactobacillus*, (I) *Akkermansia*, (J) *Alistipes*, (K) *Bacteroides*, (L) *Escherichia-Shigella*, and (M) *Enterococcus*. Data were shown as mean values ± SEM (n = 5). (N) Analysis of differences in the microbial taxa by LEfSe (LDA score > 3.5) in different groups. Signifcance was evaluated by the Kruskal-Wallis test or ANOVA with Tukey’s multiple comparisons test (*, P < 0.05, **, P < 0.01, and ***, P < 0.001).

Discussion

S. Typhimurium is an important intestinal pathogen that can cause invasive intestinal diseases such as bacterial colitis (Herp et al., 2019; Schultz et al., 2017). Antibiotics are frequently used to treat colitis caused by bacteria; nevertheless, in recent years, their abuse has greatly increased bacterial resistance, leading to serious environmental pollution. A recent study showed that antibiotic-resistance genes in probiotics could be transmitted to the intestinal microbiota, which may threaten human health (Crits-Christoph et al., 2022). It is crucial to consider the source of probiotics. Strong environmental adaptability and disease resistance make black pigs an outstanding household breed in China (Yang et al., 2022). In this study, B. velezensis HBXN2020 was isolated from the free-range feces of black piglets in a mountain village in Xianning City (Hubei, China) and exhibited excellent antibacterial activity. Otherwise, in vitro tolerance assays showed that B. velezensis HBXN2020 spores have good tolerance to high temperature, strong acids, bile salts, as well as simulated gastric and intestinal fluid, which was similar to previous research results (Du et al., 2022). Furthermore, studies for antibiotic susceptibility revealed that B. velezensis HBXN2020 is not resistant to antibiotics.

Probiotics are distinct from food or medications in that they can cause toxins or infections in the body when ingested, and they are living when swallowed (Sanders et al., 2010; Snydman, 2008). Therefore, assessing the biosafety of probiotics is crucial. In this study, the safety of B. velezensis HBXN2020 was evaluated by measuring the body weight, intestinal barrier proteins, and inflammatory cytokines of the experimented mice, as well as conducting routine blood and biochemical tests. The results showed that the expression levels of ZO-1 and occludin in the colon of mice increased after treatment with different doses of B. velezensis HBXN2020 spores. It has been reported that ZO-1, occludin and claudin are the three most important tight junction proteins in intercellular connections, which play a crucial role in maintaining the intestinal epithelial barrier (Bazzoni et al., 2000; Zihni et al., 2016). Thus, it is possible to improve intestinal barrier function by upregulating ZO-1 and occludin expression levels.

Important aminotransferases in animals, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), are regarded as critical metrics for assessing liver function damage (Gou et al., 2022; Ozer et al., 2008). Under normal circumstances, the levels of ALT and AST are in dynamic balance without notable changes. However, when the liver is damaged or becomes dysfunctional, the levels of aminotransferases (ALT and AST) increase significantly (Tang et al., 2012). Previous studies have shown that CCL4-induced liver injury strongly increases plasma ALT/AST levels (Singhal et al., 2018). Zhang et al. reported that the addition of Bacillus subtilis to chicken diets significantly decreased the serum levels of ALT and AST (Zhang et al., 2017). In this present study, the levels of ALT and AST in the probiotic-treated group were slightly lower than those in the control group, indicating that B. velezensis HBXN2020 had no negative effect on liver health in mice. The B. velezensis HBXN2020 treatment group’s blood indices were also found to be 18 comparable to those of the control group, falling within the normal reference range, according to regular blood testing.

Mice were fed with B. velezensis HBXN2020 spores orally after being challenged with S. Typhimurium ATCC14028 in order to assess the spores’ potential to alleviate colitis caused by S. Typhimurium. Our experimental results demonstrated that oral treatment with B. velezensis HBXN2020 spores could alleviate S. Typhimurium-induced colitis, as evidenced by decreased weight loss, DAI, and histological damage, which is similar to prior studies (Cao et al., 2019; Wu et al., 2022). Previous research showed that macrophages are the first line of host defense against bacterial infection. They release proinflammatory cytokines, which are critical in initiating adaptive immune responses (Cheng et al., 2014; Dinarello, 2000). Nevertheless, proinflammatory cytokines have immunological properties that can be beneficial for the host to resist the invasion of bacteria and other microbes in the surrounding environment (Liu et al., 2021). For instance, pretreatment with recombinant murine TNF-α was shown to protect mice against lethal bacterial (E. coli) infection (Cross et al., 1989). PJ-34 exerted protective effects on intestinal epithelial cells against invasive Salmonella infection by upregulating IL-6 expression through the ERK and NF-κB signal pathways (Huang, 2009).

On the other hand, some research has demonstrated that over-activation of immune cells can result in tissue damage, organ failure, systemic or persistent inflammation, and autoimmune diseases (Karki et al., 2021; Kotas and Medzhitov, 2015). IL-10 is a recognized anti-inflammatory mediator that plays a crucial role in maintaining intestinal microbe-immune homeostasis, regulating the release of inflammatory mediators, and inhibiting proinflammatory responses of innate and adaptive immunity (Maloy and Powrie, 2011; Ouyang et al., 2011; Saraiva et al., 2020). For instance, previous studies have shown that Clostridium butyrate can induce the production of IL-10 in the intestine, thereby alleviating experimental colitis in mice (Hayashi et al., 2013). Similar results were observed in our study, where oral administration of B. velezensis HBXN2020 spores reduced the expression levels of TNF-α, IL-1β, and IL-6 while increasing the levels of IL-10 in the colon of mice. Additionally, as demonstrated by the decreased histological damage and increased expression levels of intestinal barrier proteins, oral treatment of B. velezensis HBXN2020 spores reduced the functional damage of the intestinal barrier induced by S. Typhimurium infection.

Subsequently, we conducted additional analysis on the colon microbiome. Notably, oral B. velezensis HBXN2020 significantly raised the colonic microbiota’s alpha diversity. As reported in prior studies, elevated alpha diversity is associated with enhanced anti-interference ability (Chen et al., 2021). PCA analysis results showed that oral administration of B. velezensis HBXN2020 significantly affected the structure of the intestinal microbiota. Further analysis at the phylum/genus level revealed that B. velezensis HBXN2020 treatment reduced the increase of Bacteroides, Escherichia-Shigella, and Salmonella (harmful to intestinal homeostasis) in colitis (Wang et al., 2023) but enhanced the relative abundance of Lactobacillus (known for enhancing the epithelial barrier by increasing mucus secretion and upregulating the expression of tight junction proteins such as claudin-1, occludin, and ZO-1) (Kaur et al., 2021) and Akkermansia (known for modulating intestinal immune response by producing short chain fatty acids and reducing the secretion of proinflammatory cytokines) (Cani et al., 2022). Bacteroides are generally ‘friendly’ commensals in the intestine, but they can enter normal tissues through the intestinal mucosa when intestinal barrier function becomes compromised (Polk and Kasper, 1977), leading to inflammation, diarrhea, and abdominal abscesses (Pickard et al., 2017). Escherichia-Shigella is a common intestinal pathogen, and its relative abundance is associated with proinflammatory states (Morgan, 2013). Salmonella can secrete bacterial virulence proteins, which are directly delivered to the host cell cytosol through the Type III secretion system and induce the expression of pro-inflammatory cytokines (Hardt et al., 1998), leading to inflammation. Overall, the S. Typhimurium ATCC14028 infection altered the structure of the colon microbiota and raised the relative abundance of pathogenic bacteria, whereas the therapeutic B. velezensis HBXN2020 increased the abundance of beneficial bacteria, decreased inflammation, and 21 enhanced the function of the intestinal barrier.

We assessed pretreatment in order to learn more about the potential of B. velezensis HBXN2020 spores for disease prevention, given the increased efficacy of treating colitis caused by S. Typhimurium. Similarly to the therapeutic effect of oral B. velezensis HBXN2020, pretreatment with B. velezensis HBXN2020 spores effectively alleviated the symptoms of S. Typhimurium-induced colitis and reduced the expression levels of proinflammatory cytokines and increased anti-inflammatory cytokine levels in the colon of S. Typhimurium-infected mice. Furthermore, pretreatment with B. velezensis HBXN2020 spores also promoted the expression levels of intestinal barrier proteins in the colon of S. Typhimurium-infected mice. In addition, the microbiota composition was also dramatically modulated by prophylactic B. velezensis HBXN2020 in mice with colitis, although the community richness and diversity revealed by the alpha diversity index were not significantly impacted in mice with colitis by prophylactic treatment. Prophylactic B. velezensis HBXN2020 significantly boosted SCFA-producing bacteria, including Lactobacillus and Akkermansia, according to additional genus-level analysis, which was consistent with the effects of therapeutic B. velezensis HBXN2020.

Similarly, harmful bacteria such as Alistipes, Bacteroides, Escherichia-Shigella, and Enterococcus were significantly enriched in the PBS+STm group. A facultative-pathogenic bacterium called Alistipes encourages the growth of inflammation, obesity, and colorectal cancer (Parker et al., 2020). Based on those results, we found that prophylactic B. velezensis HBXN2020 alleviates S. Typhimurium-induced colitis by increasing the abundance of beneficial bacteria, attenuating proinflammatory responses of the intestine, and increasing intestinal barrier function.

Conclusion

In conclusion, gut mucosal barrier disruption and intestinal inflammation results from dysbiosis of the colonic microbiota caused by S. Typhimurium ATCC14028 infection. Supplementing Bacillus velezensis HBXN2020 can improve intestinal microbiota stability and gut barrier integrity and reduce inflammation to help prevent or treat bacterial colitis.

Experimental procedures

Animals and bacterial strains

Female specific-pathogen-free (SPF) C57BL/6 mice aged 6 to 8 weeks were purchased from the Animal Experimental Center of Huazhong Agricultural University. All mice experiments were conducted in the standard SPF facility of Huazhong Agricultural University, with 12 h of light and 12 h of darkness at a temperature of 25°C and ad libitum access to food and water. The use of animals in this experiment was approved by the Animal Care and Ethics Committee of Huazhong Agricultural University (Ethics Approval Number: HZAUMO-2023-0089).

The strains used in this study are listed in Table S3, and all the primers used in Table S4. Clostridium perfringens were cultured in a fluid thioglycollate medium (FTG) (Hopebio, Qingdao, China) at 45°C. Streptococcus suis and Pasteurella multocida were cultured in tryptic soy broth (TSB) (BD Biosciences, MD, United States) medium supplemented with 5% (v/v) sheep serum (Solarbio, Beijing, China) at 37°C, and Actinobacillus pleuropneumoniae were cultured in TSB supplemented with 5% (v/v) sheep serum and 5mM nicotinamide adenine dinucleotide (NAD) at 37°C, while the other bacterial strains were cultured in Luria Bertani (LB) medium (Solarbio, Beijing, China) at 37°C. In addition, the Difco sporulation medium (DSM) was used for inducing the sporulation of B. velezensis HBXN2020 via the nutrient depletion method (Tang et al., 2017).

Stain isolation, growth conditions and strain identification

In this study, we isolated 362 Bacillus strains from the feces of healthy piglets, and four Bacillus strains were screened through initial antibacterial tests. Then, a strain with broad-spectrum antimicrobial activity was ultimately screened out by the antibacterial spectrum assay (Table S5), and named as HBXN2020. The strain was stored in 28% glycerol at −80°C. For culturing the bacterial cells, Luria-Bertani (LB) media or agar plates supplemented with 1.5% agar were used and incubated at 37°C.

A single bacterial colony was inoculated into 10 mL of LB medium and incubated overnight at 37°C with shaking (180 rpm). The bacteria genomic DNA was extracted using the TIANamp Genomic DNA Kit (TIANGEN, Beijing, China) from bacteria. Then, 16S ribosomal sequence was amplified using 16S-specific primers and sequenced to identify the HBXN2020.

Genome sequencing, annotation and analysis

The complete genome of B. velezensis HBXN2020 was sequenced using the Illumina HiSeq PE and PacBio RSII (SMRT) platforms (Shanghai Majorbio Bio-pharm Technology Co., Ltd.). Briefly, the short reads from the Illumina HiSeq PE were assembled into contigs using SPAdenovo (http://soap.genomics.org.cn/). The long reads from the PacBio RSII and the Illumina contigs were then aligned using the miniasm and Racon tools in Unicycler (version 0.4.8, https://github.com/rrwick/Unicycler) to generate long-read sequences. During the assembly process, sequence correction was performed using Pilon (version 1.22, https://github.com/broadinstitute/pilon/wiki/Standard-Output). Lastly, a complete genome with seamless chromosomes was obtained.

The coding sequences (CDs) of the B. velezensis HBXN2020 genome were predicted using Glimmer (version 3.02, http://ccb.jhu.edu/software/glimmer/index.shtml). The tRNA and rRNA genes were predicted using TRNAscan-SE (version 2.0, http://trna.ucsc.edu/software/) and Barrnap (version 0.8, https://github.com/tseemann/barrnap), respectively. The functional annotation of all CDSs was performed using various databases, including Swiss-Prot Database (https://web.expasy.org/docs/swiss-prot_guideline.html), Pfam Database (http://pfam.xfam.org/), EggNOG Database (http://eggnog.embl.de/), GO Database (http://www.geneontology.org/), and KEGG Database (http://www.genome.jp/kegg/). The circular map of the B. velezensis HBXN2020 genome was generated using CGView (version 2, http://wishart.biology.ualberta.ca/cgview/) (Stothard and Wishart, 2005).

Comparative genomic analysis

To elucidate the phylogenetic relationships from a whole-genome perspective, a phylogenetic tree based on the whole genome was constructed using the Type (Strain) Genome Server (TYGS) online (https://ggdc.dsmz.de/) (Meier-Kolthoff et al., 2022). The average nucleotide identity (ANI) values of genome to genome were calculated using the JSpeciesWS online service (Richter et al., 2016), and a heatmap was then generated using TBtools (version 1.113) (Chen et al., 2020).

Growth curves of B. velezensis HBXN2020

The growth curve of B. velezensis HBXN2020 was recorded in flat-bottomed 100-well microtiter plates via detecting optical density at 600 nm (OD₆₀₀) at 1 h intervals using the automatic growth curve analyzer (Bioscreen, Helsinki, Finland).

Antimicrobial Assays

The in vitro antagonistic activity of B. velezensis HBXN2020-CFS was tested using the agar well-diffusion method against 18 indicator strains (pathogens), which included 7 standard strains (E. coli ATCC 25922, E. coli ATCC 35150, S. Typhimurium ATCC 14028 (STm), S. Typhimurium SL1344, S. aureus ATCC 29213, S. aureus ATCC 43300, and C. perfringens CVCC 2030) and 11 clinical isolates (E. coli EC024, S. Enteritidis SE006, S. aureus S21, C. perfringens CP023, C. perfringens CP002, S. suis SC19, S. suis SS006, P. multocida PM002, P. multocida PM008, A. pleuropneumoniae APP015, and A. pleuropneumoniae APP017). All plates were cultured at 37°C for 16 h before observing the inhibition zone, and the diameter of the inhibition zone was measured using a vernier caliper. The presence of a clear zone indicated antagonistic activity.

Antibiotic susceptibility assays

Antimicrobial susceptibility testing was performed using the Kirby-Bauer (KB) disk diffusion method in accordance with the Clinical Laboratory Standards Institute (CLSI) guidelines (CLSI., 2018.). The antimicrobial agents tested were: Ampicillin, Meropenem, Piperacillin, Gentamycin, Tetracycline, Doxycycline, Minocycline, Erythromycin, Enrofloxacin, Ofloxacin, Sulfamethoxazole, Trimethoprim-sulfamethoxazole, Polymyxin B, Teicoplanin, Trimethoprim, Florfenicol, Spectinomycin, Nitrofurantoin, and Rifampicin. The diameter of the inhibition zone was measured using a vernier caliper.

In vitro resistance assay of B. velezensis HBXN2020

B. velezensis HBXN2020 spores (100 μL) or vegetative cells (100 μL) were separately resuspended in 900 μL of LB medium supplemented with different pH values (2, 3, 4, 5 or 6), bile salts (0.85% NaCl, 0.3%), simulated gastric fluid (SGF, HCl, pH 1.2) containing 10 g L^-1 of pepsin in 0.85% NaCl solution, or simulated intestinal fluid (SIF, NaOH, pH 6.8) containing 10 g L^-1 of trypsin in 0.05 M KH2PO4 solution, and incubated at 37 °C. A normal LB medium (pH 7.0) was used as the control. At predetermined time points, 100 μL was taken from each sample, serially diluted 10-fold with sterile PBS (pH 7.2), and then spread onto LB agar plates. The plates were incubated overnight in a constant temperature incubator at 37°C, and the bacterial colonies were counted. The survival rate was calculated using the following formula: Survival rate = (number of bacteria in the treatment group/number of bacteria in the control group) × 100%.

One milliliter of B. velezensis HBXN2020 spores or vegetative cells were separately placed in water baths at different temperatures (37°C, 45°C, 55°C, 65°C, 75°C, 85°C or 95°C) for 20 min, with a 37°C water bath used as the control. The survival rate was calculated as described above.

In vitro bacterial competition

To investigate whether B. velezensis HBXN2020 directly inhibited the growth of STm, we performed spot-on lawn and agar-well diffusion assays, as well as co-culture assays in liquid culture medium. In the spot-on lawn antimicrobial assays, we prepared double layers of agar by first pouring LB agar into the plate as the bottom layer. The top layer consisted of 10 mL TSB broth containing 0.7% agar with STm overnight culture. Then, 10 μL of B. velezensis HBXN2020 overnight culture and cell-free supernatant (CFS) were respectively spotted onto TSB agar and incubated at 37°C for 12 h to measure the inhibition zone. A transparent zone of at least 1 mm around the spot was considered positive.

The antagonistic effect of B. velezensis HBXN2020-CFS against STm was determined using the agar-well diffusion assays. To collect B. velezensis HBXN2020-CFS, the culture was centrifuged at 9,000g for 15 min at 4°C, and the supernatant was filtered through a 0.22 μm membrane filter (Millipore, USA). The STm lawn medium was prepared by mixing 10 mL of TSB broth containing 0.7% agar with STm overnight culture and then poured into a sterile plate covered with LB agar and Oxford cups, 8 mm diameter wells were prepared in the TSB agar after removing the cups. The wells were filled with 100 μL of B. velezensis HBXN2020-CFS, LB medium or ampicillin (100 µg mL^-1). The plates were incubated at 37°C for 14 h, and the inhibition zone was measured.

The co-culture assay was conducted by incubating B. velezensis HBXN2020 and S. Typhimurium ATCC14028 (carry pET28a (+), kanamycin resistance) (Cao et al., 2019) separately overnight at 37°C and diluting them to 10⁴ CFU/mL. Then, the two strains were mixed at different ratios (1:1, 1:10, 1:50 or 1:100) and co-cultured at 37°C with shaking (180 rpm). At predetermined time points, serial 10-fold dilutions were prepared for all samples and spread onto selective (kanamycin 50 µg mL^-1) LB agar plates and cultured at 37°C for 12 h before bacterial counting. Viable colony counts ranged from 30 to 300 per plate.

Biosafety assessment

Biosafety assay of B. velezensis HBXN2020 referred to the method described by Zhou et al.(Zhou et al., 2022) with slight modifications. After a 7-day acclimation period (free access to water and food), mice were randomly divided into four treatment groups (n = 5): low-dose B. velezensis HBXN2020 spores group (L-HBXN2020 group, 10⁷ CFU/mouse), medium-dose B. velezensis HBXN2020 spores group (M-HBXN2020 group, 10⁸ CFU/mouse), high-dose B. velezensis HBXN2020 spores group (H-HBXN2020 group, 10⁹ CFU/mouse), and a control group. During the experimental period (15 days), mice were weighed and orally gavaged with their respective treatments once every two days. On day 15, all mice were euthanized, and blood, heart, liver, spleen, lung, kidney, ileum, cecum, and colon were collected. Blood samples were used for routine blood and biochemistry tests. Major organ tissues (heart, liver, spleen, lung, and kidney) and a 5-mm distal segment of the colon were used for histopathology. The remaining colonic tissues were rapidly frozen in liquid nitrogen and stored at −80°C for cytokine and tight junction protein expression analysis.

Salmonella Typhimurium-induced mouse model of colitis

After 7 days of acclimation (free access to water and food), mice were randomly divided into three treatment groups (n = 8): Control group, STm + PBS group, and STm + HBXN2020 group. The S. Typhimurium-induced colitis was performed as previously described (Stecher et al., 2005), with slight modifications. On the first day of the experiment, all mice in the STm + PBS group and STm + HBXN2020 group were orally inoculated with 200 μL (5×10⁷ CFU/mouse) of STm. On days 1, 3 and 5 following STm infection, each mouse in the STm + HBXN2020 group received 200 μL (1×10⁸ CFU/mouse) of B. velezensis HBXN2020 spores via gavage administration. In contrast, the control group and STm + PBS group received 200 μL of sterile PBS by oral gavage. Fecal samples were collected daily following STm infection and resuspended in sterile PBS. The number of STm in mice feces from both the STm + PBS and STm + HBXN2020 groups was then determined by spreading a serial 10-fold dilution on selective LB agar plates containing 50 µg mL^-1 kanamycin. Throughout the entire experiment, the body weight, stool consistency and fecal occult blood of all mice were monitored daily. As shown in Table S6, disease activity index (DAI) was calculated by the sum of the scores from three parameters (Praveschotinunt et al., 2019). On day 7 after STm infection, all mice were euthanized, their ileum, cecum and colon were collected. The length of colon was measured, and a 5-mm distal segment of the colon was fixed in 4% paraformaldehyde for further histopathology. The remaining colon was then rapidly frozen in liquid nitrogen and stored at −80°C for cytokine and tight junction protein expression analysis. Then, the number of STm in the ileum, cecum, and colon was determined by spreading serial 10-fold dilutions on selective LB agar plates.

To investigate the prophylactic efficacy of B. velezensis HBXN2020 in ameliorating STm-induced colitis, another independent experiment was conducted using six-week-old female C57BL/6 mice (SPF). After a seven-day acclimation period, mice were randomly assigned to three groups (n = 8): control group, PBS + STm group and HBXN2020 + STm group. On days 1, 3, 5 and 7, each mouse in the HBXN2020 + STm group received 200 μL (1×10⁸ CFU/mouse) of B. velezensis HBXN2020 spores via gavage administration. Meanwhile, mice in the control group and PBS + STm group received 200 μL of sterile PBS by oral gavage. On day 7, all mice in the PBS + STm group and HBXN2020 + STm group were orally inoculated with 200 μL (5×10⁷ CFU/mouse) of STm. Fecal samples were collected daily following STm infection from both groups and resuspended in sterile PBS. The number of STm in the feces of mice was then determined by spreading serial 10-fold dilutions on selective LB agar plates (50 µg mL^-1 kanamycin). Throughout the entire experiment, the body weight and DAI scores of all mice were monitored daily. On day 12, all mice were euthanized, and the ileum, cecum, and colon were collected. The colon length was measured, and a 5-mm distal segment of the colon was fixed in 4% formalin for sectioning and staining. The remaining colon was stored at −80°C for future analysis. Lastly, the number of STm in the ileum, cecum, and colon was determined using a selective LB agar plate.

Determination of cytokines and tight junction protein expression in colon tissue

Total RNA was extracted from colon tissues using TRIpure reagent (Aidlab, China), and cDNA was obtained using HiScript^® III RT SuperMix for qPCR (+gDNA wiper) (Vazyme, China). RT-qPCR for each gene was performed in triplicate using qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China). The relative expression level of cytokine and tight junction protein genes was calculated using the 2^−ΔΔCt method with β-actin and GAPDH as reference genes. The primer sequences used in the RT-qPCR test are listed in Table S4.

Histopathology analysis

Colon tissue samples (0.5 cm) were fixed in 4% paraformaldehyde for 24 h, and the fixed tissues were then embedded in paraffin and sectioned. The sections were stained with hematoxylin and eosin (H&E) and observed and imaged using an optical microscope (Olympus Optical, Tokyo, Japan). The histopathological score included the degree of inflammatory infiltration, changes in crypt structures, and the presence or absence of ulceration and edema. The scoring criteria were determined as previously described (Wu et al., 2022).

16S rRNA gene sequencing and analysis

According to the manufacturer’s instructions, colon microbial community genomes were extracted using E.Z-N.A ® Stool DNA Kit (Omega; D4015-01), and quality was detected by 1% agarose gel electrophoresis. The 16S rRNA V3-V4 variable region was amplified by PCR using universal primers 338F (5 ‘- ACTCCTACGGGGGGCAG-3’) and 806R (5 ‘-GACTACHVGGGTWTCTAAT-3’). The PCR products were examined by electrophoresis on 2% agarose gels and then purified with the AxyPrep DNA gel extraction kit (Axygen Biosciences, USA). A sequencing library was constructed using the NEXTFLEX® Rapid DNA-Seq Kit, and sequencing was performed using the Illumina MiSeq platform. Raw reads were quality evaluated and filtered by fastp (version 0.20.0) and merged using FLASH (version 1.2.7). The optimized sequences were clustered into operational taxonomic units (OTUs) based on 97% sequence similarity using UPARSE (version 7.1). The representative sequences of each OTU was classified by RDP classifier (version 2.2; confidence threshold value, 0.7). Alpha diversity was assessed using the ACE, chao, Shannon, and Simpson indices. The β-diversity analysis was performed using Bray-Curtis distances and visualized through principal component analysis (PCA). Linear discriminant analysis (LDA) effect size (LefSe) was used to identify differential microbiota between groups.

Statistical Analysis

Statistical analysis was performed using GraphPad Prism 8.3.0 (GraphPad Software, San Diego, CA, USA) and Excel (Microsoft, Redmond, USA). Data are presented as mean ± standard error of the mean (SEM). Differences between two groups were evaluated using two-tailed unpaired Student’s t-test, and all other comparisons were conducted using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test. For all analyses, significance differences are denoted as: *, P < 0.05, **, P < 0.01, and ***, P < 0.001.

Data availability

The datasets supporting the conclusions of this article were deposited in the NCBI Sequence Read Archive database under the accession numbers: CP119399.1 (whole genome sequencing raw data) and PRJNA1045315 (microbiota raw sequencing data).

Conflict of interest

We declare no conflict of interest.

Acknowledgements

This work was supported by grants from the National Program on Key Research Project of China (2021YFD1800300, 2022YFD1800800), “Yingzi Tech & Huazhong Agricultural University Intelligent Research Institute of Food Health” (No. IRIFH202209; IRIFH202301), and the Fundamental Research Funds for the Central Universities (2662016PY004).

Author contributions

Linkang Wang: Conceptualization, Methodology, Data curation, Formal analysis, Writing - original draft. Haiyan Wang, Xinxin Li, Mengyuan Zhu: Methodology, Data curation, Planned and performed the experiments. Dongyang Gao, Dayue Hu, Zhixuan Xiong: Methodology, Writing - Reviewing and Editing. Xiangmin Li: Supervision, Writing-reviewing and editing. Ping Qian: Conceptualization, Funding acquisition, Project administration, Supervision, Writing-Reviewing and Editing. All authors read and approved the submitted version of the paper.

References

1. Abdhul K.
2. Ganesh M.
3. Shanmughapriya S.
4. Vanithamani S.
5. Kanagavel M.
6. Anbarasu K.
7. Natarajaseenivasan K
2015Bacteriocinogenic potential of a probiotic strain Bacillus coagulans [BDU3] from NgariInt J Biol Macromol 79:800–806
1. Bazzoni G.
2. Martinez-Estrada O.M.
3. Orsenigo F.
4. Cordenonsi M.
5. Citi S.
6. Dejana E
2000Interaction of junctional adhesion molecule with the tight junction components ZO-1, cingulin, and occludinJ Biol Chem 275:20520–20526
1. Cani P.D.
2. Depommier C.
3. Derrien M.
4. Everard A.
5. de Vos W.M.
2022Akkermansia muciniphila: paradigm for next-generation beneficial microorganismsNat Rev Gastroenterol Hepatol 19:625–637
1. Cao Z.
2. Wang X.
3. Pang Y.
4. Cheng S.
5. Liu J.
2019Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatmentNat Commun 10
1. Chen C.
2. Chen H.
3. Zhang Y.
4. Thomas H.R.
5. Frank M.H.
6. He Y.
7. Xia R
2020TBtools: An Integrative Toolkit Developed for Interactive Analyses of Big Biological DataMol Plant 13:1194–1202
1. Chen L.
2. Wang D.
3. Garmaeva S.
4. Kurilshikov A.
5. Vich Vila A.
6. Gacesa R.
7. Sinha T.
8. Segal E.
9. Weersma R.K.
10. Wijmenga C.
11. et al.
2021The long-term genetic stability and individual specificity of the human gut microbiomeCell 184:2302–2315
1. Cheng A.
2. Yan H.
3. Han C.
4. Wang W.
5. Tian Y.
6. Chen X
2014Polyphenols from blueberries modulate inflammation cytokines in LPS-induced RAW264.7 macrophagesInt J Biol Macromol 69:382–387
1. CLSI
2018Performance standards for antimicrobial disk susceptibility tests, M02, 13th edWayne, PA: Clinical and Laboratory Standards Institute
1. Cristofori F.
2. Dargenio V.N.
3. Dargenio C.
4. Miniello V.L.
5. Barone M.
6. Francavilla R
2021Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the BodyFront Immunol 12
1. Crits-Christoph A.
2. Hallowell H.A.
3. Koutouvalis K.
4. Suez J
2022Good microbes, bad genes? The dissemination of antimicrobial resistance in the human microbiomeGut Microbes 14
1. Cross A.S.
2. Sadoff J.C.
3. Kelly N.
4. Bernton E.
5. Gemski P.
1989Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infectionJ Exp Med 169:2021–2027
1. Dinarello C.A
2000Proinflammatory cytokinesChest 118:503–508
1. Du H.
2. Yao W.
3. Kulyar M.F.
4. Ding Y.
5. Zhu H.
6. Pan H.
7. Li K.
8. Bhutta Z.A.
9. Liu S.
10. Li J
2022Effects of Bacillus amyloliquefaciens TL106 Isolated from Tibetan Pigs on Probiotic Potential and Intestinal Microbes in Weaned PigletsMicrobiol Spectr 10
1. Fabrega A.
2. Vila J
2013Salmonella enterica serovar Typhimurium skills to succeed in the host: virulence and regulationClin Microbiol Rev 26:308–341
1. Ferri M.
2. Ranucci E.
3. Romagnoli P.
4. Giaccone V
2017Antimicrobial resistance: A global emerging threat to public health systemsCrit Rev Food Sci Nutr 57:2857–2876
1. Gou S.
2. Chen N.
3. Wu X.
4. Zu M.
5. Yi S.
6. Ying B.
7. Dai F.
8. Ke B.
9. Xiao B
2022Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen self-producing capacities for multimodal synergistic cancer therapyActa Pharm Sin B 12:406–423
1. Gu S.B.
2. Zhao L.N.
3. Wu Y.
4. Li S.C.
5. Sun J.R.
6. Huang J.F.
7. Li D.D
2015Potential probiotic attributes of a new strain of Bacillus coagulans CGMCC 9951 isolated from healthy piglet fecesWorld J Microbiol Biotechnol 31:851–863
1. Hardt W.D.
2. Chen L.M.
3. Schuebel K.E.
4. Bustelo X.R.
5. Galán J.E
1998S. typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cellsCell 93:815–826
1. Hayashi A.
2. Sato T.
3. Kamada N.
4. Mikami Y.
5. Matsuoka K.
6. Hisamatsu T.
7. Hibi T.
8. Roers A.
9. Yagita H.
10. Ohteki T.
11. et al.
2013A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in miceCell Host Microbe 13:711–722
1. Herp S.
2. Brugiroux S.
3. Garzetti D.
4. Ring D.
5. Jochum L.M.
6. Beutler M.
7. Eberl C.
8. Hussain S.
9. Walter S.
10. Gerlach R.G.
11. et al.
2019Mucispirillum schaedleri Antagonizes Salmonella Virulence to Protect Mice against ColitisCell Host Microbe 25:681–694
1. Huang F.C
2009Upregulation of Salmonella-induced IL-6 production in Caco-2 cells by PJ-34, PARP-1 inhibitor: involvement of PI3K, p38 MAPK, ERK, JNK, and NF-kappaBMediators Inflamm 2009
1. Karki R.
2. Sharma B.R.
3. Tuladhar S.
4. Williams E.P.
5. Zalduondo L.
6. Samir P.
7. Zheng M.
8. Sundaram B.
9. Banoth B.
10. Malireddi R.K.S.
11. et al.
2021Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock SyndromesCell 184:149–168
1. Katiyo S.
2. Muller-Pebody B.
3. Minaji M.
4. Powell D.
5. Johnson A.P.
6. De Pinna E.
7. Day M.
8. Harris R.
9. Godbole G.
2019Epidemiology and Outcomes of Nontyphoidal Salmonella Bacteremias from England, 2004 to 2015J Clin Microbiol 57
1. Kaur H.
2. Gupta T.
3. Kapila S.
4. Kapila R
2021Protective effects of potential probiotic Lactobacillus rhamnosus (MTCC-5897) fermented whey on reinforcement of intestinal epithelial barrier function in a colitis-induced murine modelFood Funct 12:6102–6116
1. Kotas M.E.
2. Medzhitov R
2015Homeostasis, inflammation, and disease susceptibilityCell 160:816–827
1. Li A.
2. Wang Y.
3. Li Z.
4. Qamar H.
5. Mehmood K.
6. Zhang L.
7. Liu J.
8. Zhang H.
9. Li J
2019Probiotics isolated from yaks improves the growth performance, antioxidant activity, and cytokines related to immunity and inflammation in miceMicrob Cell Fact 18
1. Liu C.
2. Chu D.
3. Kalantar-Zadeh K.
4. George J.
5. Young H.A.
6. Liu G
2021Cytokines: From Clinical Significance to QuantificationAdv Sci (Weinh 8
1. Maloy K.J.
2. Powrie F
2011Intestinal homeostasis and its breakdown in inflammatory bowel diseaseNature 474:298–306
1. Meier-Kolthoff J.P.
2. Carbasse J.S.
3. Peinado-Olarte R.L.
4. Goker M
2022TYGS and LPSN: a database tandem for fast and reliable genome-based classification and nomenclature of prokaryotesNucleic Acids Res 50:D801–D807
1. Mohan A.
2. Munusamy C.
3. Tan Y.C.
4. Muthuvelu S.
5. Hashim R.
6. Chien S.L.
7. Wong M.K.
8. Khairuddin N.A.
9. Podin Y.
10. Lau P.S.
11. et al.
2019Invasive Salmonella infections among children in Bintulu, Sarawak, Malaysian Borneo: a 6-year retrospective reviewBMC Infect Dis 19
1. Morgan K.L
2013Infection, illness, and fenugreek seeds: was illness a good enough proxy for infection in the 2011 outbreak of shiga toxin-producing Escherichia coli O104:H4 in France?Clin Infect Dis 56:1055–1056
1. Ohland C.L.
2. Macnaughton W.K
2010Probiotic bacteria and intestinal epithelial barrier functionAm J Physiol Gastrointest Liver Physiol 298:G807–819
1. Ouattara H.G.
2. Reverchon S.
3. Niamke S.L.
4. Nasser W
2017Regulation of the synthesis of pulp degrading enzymes in Bacillus isolated from cocoa fermentationFood Microbiol 63:255–262
1. Ouyang W.
2. Rutz S.
3. Crellin N.K.
4. Valdez P.A.
5. Hymowitz S.G
2011Regulation and functions of the IL-10 family of cytokines in inflammation and diseaseAnnu Rev Immunol 29:71–109
1. Ozer J.
2. Ratner M.
3. Shaw M.
4. Bailey W.
5. Schomaker S
2008The current state of serum biomarkers of hepatotoxicityToxicology 245:194–205
1. Parker B.J.
2. Wearsch P.A.
3. Veloo A.C.M.
4. Rodriguez-Palacios A
2020The Genus Alistipes: Gut Bacteria With Emerging Implications to Inflammation, Cancer, and Mental HealthFront Immunol 11
1. Paulson J.A.
2. Zaoutis T.E.
3. Council on Environmental, H., and Committee on Infectious, D
2015Nontherapeutic Use of Antimicrobial Agents in Animal Agriculture: Implications for PediatricsPediatrics 136:e1670–1677
1. Pickard J.M.
2. Zeng M.Y.
3. Caruso R.
4. Núñez G
2017Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory diseaseImmunol Rev 279:70–89
1. Polk B.F.
2. Kasper D.L
1977Bacteroides fragilis subspecies in clinical isolatesAnn Intern Med 86:569–571
1. Praveschotinunt P.
2. Duraj-Thatte A.M.
3. Gelfat I.
4. Bahl F.
5. Chou D.B.
6. Joshi N.S
2019Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gutNat Commun 10
1. Reyman M.
2. van Houten M.A.
3. Watson R.L.
4. Chu M.
5. Arp K.
6. de Waal W.J.
7. Schiering I.
8. Plotz F.B.
9. Willems R.J.L.
10. van Schaik W.
11. et al.
2022Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trialNat Commun 13
1. Richter M.
2. Rossello-Mora R.
3. Oliver Glockner F.
4. Peplies J
2016JSpeciesWS: a web server for prokaryotic species circumscription based on pairwise genome comparisonBioinformatics 32:929–931
1. Sanders M.E.
2. Akkermans L.M.
3. Haller D.
4. Hammerman C.
5. Heimbach J.
6. Hormannsperger G.
7. Huys G.
8. Levy D.D.
9. Lutgendorff F.
10. Mack D.
11. et al.
2010Safety assessment of probiotics for human useGut Microbes 1:164–185
1. Saraiva M.
2. Vieira P.
3. O’Garra A
2020Biology and therapeutic potential of interleukin-10J Exp Med 217
1. Schultz B.M.
2. Paduro C.A.
3. Salazar G.A.
4. Salazar-Echegarai F.J.
5. Sebastian V.P.
6. Riedel C.A.
7. Kalergis A.M.
8. Alvarez-Lobos M.
9. Bueno S.M
2017A Potential Role of Salmonella Infection in the Onset of Inflammatory Bowel DiseasesFront Immunol 8
1. Shao J.
2. Liu Y.
3. Xie J.
4. Stefanic P.
5. Lv Y.
6. Fan B.
7. Mandic-Mulec I.
8. Zhang R.
9. Shen Q.
10. Xu Z
2022Annulment of Bacterial Antagonism Improves Plant Beneficial Activity of a Bacillus velezensis ConsortiumAppl Environ Microbiol 88
1. Singhal M.
2. Liu X.
3. Inverso D.
4. Jiang K.
5. Dai J.
6. He H.
7. Bartels S.
8. Li W.
9. Abdul Pari A.A.
10. Gengenbacher N.
11. et al.
2018Endothelial cell fitness dictates the source of regenerating liver vasculatureJ Exp Med 215:2497–2508
1. Snydman D.R
2008The safety of probioticsClin Infect Dis 46:S104–111
1. Stecher B.
2. Macpherson A.J.
3. Hapfelmeier S.
4. Kremer M.
5. Stallmach T.
6. Hardt W.D
2005Comparison of Salmonella enterica serovar Typhimurium colitis in germfree mice and mice pretreated with streptomycinInfect Immun 73:3228–3241
1. Stothard P.
2. Wishart D.S
2005Circular genome visualization and exploration using CGViewBioinformatics 21:537–539
1. Tang Y.
2. Gao C.
3. Xing M.
4. Li Y.
5. Zhu L.
6. Wang D.
7. Yang X.
8. Liu L.
9. Yao P
2012Quercetin prevents ethanol-induced dyslipidemia and mitochondrial oxidative damageFood Chem Toxicol 50:1194–1200
1. Tang Z.
2. Sun H.
3. Chen T.
4. Lin Z.
5. Jiang H.
6. Zhou X.
7. Shi C.
8. Pan H.
9. Chang O.
10. Ren P.
11. et al.
2017Oral delivery of Bacillus subtilis spores expressing cysteine protease of Clonorchis sinensis to grass carp (Ctenopharyngodon idellus): Induces immune responses and has no damage on liver and intestine functionFish Shellfish Immunol 64:287–296
1. Wang L.
2. Gou X.
3. Ding Y.
4. Liu J.
5. Wang Y.
6. Wang Y.
7. Zhang J.
8. Du L.
9. Peng W.
10. Fan G
2023The interplay between herbal medicines and gut microbiota in metabolic diseasesFront Pharmacol 14
1. Wang Y.
2. Xie Q.
3. Zhang Y.
4. Ma W.
5. Ning K.
6. Xiang J.Y.
7. Cui J.
8. Xiang H
2020Combination of probiotics with different functions alleviate DSS-induced colitis by regulating intestinal microbiota, IL-10, and barrier functionAppl Microbiol Biotechnol 104:335–349
1. Wu J.
2. Lin Z.
3. Wang X.
4. Zhao Y.
5. Zhao J.
6. Liu H.
7. Johnston L.J.
8. Lu L.
9. Ma X
2022Limosilactobacillus reuteri SLZX19-12 Protects the Colon from Infection by Enhancing Stability of the Gut Microbiota and Barrier Integrity and Reducing InflammationMicrobiol Spectr 10
1. Yang W.
2. Liu Z.
3. Zhao Q.
4. Du H.
5. Yu J.
6. Wang H.
7. Liu X.
8. Liu H.
9. Jing X.
10. Yang H.
11. et al.
2022Population Genetic Structure and Selection Signature Analysis of Beijing Black PigFront Genet 13
1. Yang W.H.
2. Westman J.S.
3. Heithoff D.M.
4. Sperandio M.
5. Cho J.W.
6. Mahan M.J.
7. Marth J.D
2021Neu3 neuraminidase induction triggers intestinal inflammation and colitis in a model of recurrent human food-poisoningProc Natl Acad Sci U S A 118
1. Ye M.
2. Tang X.
3. Yang R.
4. Zhang H.
5. Li F.
6. Tao F.
7. Li F.
8. Wang Z
2018Characteristics and Application of a Novel Species of Bacillus: Bacillus velezensisACS Chem Biol 13:500–505
1. Zhang D.X.
2. Kang Y.H.
3. Zhan S.
4. Zhao Z.L.
5. Jin S.N.
6. Chen C.
7. Zhang L.
8. Shen J.Y.
9. Wang C.F.
10. Wang G.Q.
11. et al.
2019Effect of Bacillus velezensis on Aeromonas veronii-Induced Intestinal Mucosal Barrier Function Damage and Inflammation in Crucian Carp (Carassius auratus)Front Microbiol 10
1. Zhang L.
2. Bai K.
3. Zhang J.
4. Xu W.
5. Huang Q.
6. Wang T
2017Dietary effects of Bacillus subtilis fmbj on the antioxidant capacity of broilers at an early agePoult Sci 96:3564–3573
1. Zhou J.
2. Li M.
3. Chen Q.
4. Li X.
5. Chen L.
6. Dong Z.
7. Zhu W.
8. Yang Y.
9. Liu Z.
10. Chen Q
2022Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral deliveryNat Commun 13
1. Zihni C.
2. Mills C.
3. Matter K.
4. Balda M.S
2016Tight junctions: from simple barriers to multifunctional molecular gatesNat Rev Mol Cell Biol 17:564–580

Article and author information

Author information

Linkang Wang
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
Haiyan Wang
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
Xinxin Li
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
Mengyuan Zhu
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
Dongyang Gao
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
Dayue Hu
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
Zhixuan Xiong
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
Xiangmin Li
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
- Corresponding author: Ping Qian: Tel: 86-27-87282608; Fax: 86-27-87282608; E-mail: qianp@mail.hzau.edu.cn. Address: No. 1, Shizishan Street, Hongshan District, Wuhan City, Hubei Province, China. Co-corresponding author: Xiang-min Li: Tel: 86-27-87282608; Fax: 86-27-87282608; E-mail: lixiangmin@mail.hzau.edu.cn. Address: No. 1, Shizishan 1 Street, Hongshan District, Wuhan City, Hubei Province, China.
Ping Qian
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, Hubei, 430070, People’s Republic of China, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, People’s Republic of China, Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, People’s Republic of China
- Corresponding author: Ping Qian: Tel: 86-27-87282608; Fax: 86-27-87282608; E-mail: qianp@mail.hzau.edu.cn. Address: No. 1, Shizishan Street, Hongshan District, Wuhan City, Hubei Province, China. Co-corresponding author: Xiang-min Li: Tel: 86-27-87282608; Fax: 86-27-87282608; E-mail: lixiangmin@mail.hzau.edu.cn. Address: No. 1, Shizishan 1 Street, Hongshan District, Wuhan City, Hubei Province, China.

Version history

Preprint posted: November 21, 2023
Sent for peer review: November 21, 2023
Reviewed Preprint version 1: March 12, 2024
Reviewed Preprint version 2: June 5, 2024
Reviewed Preprint version 3: October 11, 2024
Version of Record published: November 19, 2024

Copyright

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

views: 460
downloads: 127
citations: 0

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Significance of findings

Strength of evidence

Abstract

Introduction

Results

Genomic Characteristics

Genomic characteristics and phylogenetic relationships of B. velezensis HBXN2020.

Growth curve and in vitro resistance against environmental assaults

Growth curve of B. velezensis HBXN2020 and its in vitro resistance against environmental assaults.

Antibiotic susceptibility of B. velezensis HBXN2020 and bacteriostasis effect in vitro

Antibiotic susceptibility of B. velezensisHBXN2020 and bacteriostasis assay in vitro.

Biosafety evaluation of B. velezensis HBXN2020

In vivo safety evaluation of B. velezensis HBXN2020 in a mouse model.

Oral administration of B. velezensis HBXN2020 spores alleviated S. Typhimurium-induced colitis

Oral B. velezensis HBXN2020 spores alleviated S. Typhimurium-induced experimental mouse colitis.

Oral B. velezensis HBXN2020 spores attenuated colonic damage and inflammatory reaction.

Oral B. velezensis HBXN2020 spores regulated the composition of intestinal microbiota.